- Home
- ZYME
ZYME
Zymeworks Inc.
as 12-18-2024 11:45am EST
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | MIDDLETOWN |
| Market Cap: | 751.6M | IPO Year: | 2017 |
| Target Price: | $18.83 | AVG Volume (30 days): | 416.1K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.97 - $17.70 | Next Earning Date: | 10-31-2024 |
| Revenue: | $62,199,000 | Revenue Growth: | -86.52% |
| Revenue Growth (this year): | 21.53% | Revenue Growth (next year): | -1.00% |
Latest Zymeworks Inc. News
ZYME Breaking Stock News: Dive into ZYME Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans
GlobeNewswire
6 days ago
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
GlobeNewswire
a month ago
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewswire
a month ago
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
GlobeNewswire
a month ago
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
Simply Wall St.
2 months ago
Zymeworks Third Quarter 2024 Earnings: Revenues Disappoint
Simply Wall St.
2 months ago
Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year
GlobeNewswire
2 months ago
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Compare ZYME vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZYME Zymeworks Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.